Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.676
-0.017 (-2.52%)
At close: Feb 21, 2025, 4:00 PM
0.700
+0.024 (3.54%)
After-hours: Feb 21, 2025, 7:58 PM EST
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Lineage Cell Therapeutics stock have an average target of 4.50, with a low estimate of 2.00 and a high estimate of 9.00. The average target predicts an increase of 565.68% from the current stock price of 0.68.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $3 → $2 | Strong Buy | Maintains | $3 → $2 | +195.86% | Feb 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +1,231.36% | Jan 31, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $5 → $3 | Strong Buy | Maintains | $5 → $3 | +343.79% | Jan 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +195.86% | Jan 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $9 | Strong Buy | Maintains | $7 → $9 | +1,231.36% | Dec 4, 2024 |
Financial Forecast
Revenue This Year
8.42M
from 8.95M
Decreased by -5.88%
Revenue Next Year
11.88M
from 8.42M
Increased by 41.15%
EPS This Year
-0.11
from -0.12
EPS Next Year
-0.11
from -0.11
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 10.9M | 26.7M | 38.0M | |||
| Avg | 8.4M | 11.9M | 16.1M | |||
| Low | 7.3M | 3.3M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 22.2% | 216.8% | 219.9% | |||
| Avg | -5.9% | 41.1% | 35.7% | |||
| Low | -18.2% | -61.1% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.12 | -0.04 | 0.01 | |||
| Avg | -0.11 | -0.11 | -0.09 | |||
| Low | -0.12 | -0.17 | -0.20 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.